The International Congress on Parkinson's Disease (ICPD) represents one of the most significant gatherings in the neurodegenerative disease research calendar. Organized by the International Parkinson and Movement Disorders Society (IPMDS), this premier congress brings together the global community of clinicians, researchers, scientists, and patient advocates dedicated to understanding, treating, and ultimately preventing Parkinson's disease[1].
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the cardinal motor symptoms of bradykinesia, resting tremor, rigidity, and postural instability. Beyond motor manifestations, Parkinson's involves a spectrum of non-motor symptoms including cognitive impairment, depression, sleep disorders, autonomic dysfunction, and sensory disturbances that significantly impact quality of life[2][3].
The International Congress on Parkinson's Disease provides a comprehensive forum for:
The Congress serves as a critical platform for the IPMDS to fulfill its mission of promoting research, education, and clinical care for movement disorders worldwide[1:1].
The ICPD features multiple session formats designed to address diverse educational and scientific needs:
Keynote Lectures
Plenary Sessions
Parallel Symposia
Oral Communications
Poster Sessions
Workshops
The Congress covers the full spectrum of Parkinson's research and clinical care:
Basic Science
Clinical Research
Therapeutics
Non-Motor Symptoms
Healthcare Delivery
The development of therapies that can slow or halt Parkinson's progression represents the field's highest priority, and the ICPD regularly features the latest advances:
The alpha-synuclein protein remains the central therapeutic target in Parkinson's disease:
Immunotherapy
Small Molecule Modulators
Gene Therapy Approaches
The LRRK2 protein kinase represents a major therapeutic target:
Kinase Inhibitors
Rationale
Glucocerebrosidase (GBA) mutations are significant risk factors:
Enzyme Replacement/Enhancement
Multiple approaches aim to protect vulnerable neurons:
Anti-Inflammatory
Mitochondrial Protectants
Growth Factors
Early and accurate diagnosis enables timely intervention:
Alpha-Synuclein Assays
Neurodegeneration Markers
Inflammatory Markers
Dopaminergic Imaging
Structural Imaging
Functional Imaging
Wearable and smartphone-based assessments:
DBS remains a cornerstone of advanced Parkinson's management:
Targets
Advances
Incisional lesioning technology:
Viral vector-based approaches:
Recognition of non-motor features has grown substantially[10]:
Mild Cognitive Impairment
Parkinson's Disease Dementia
The ICPD addresses critical issues in clinical research:
Motor Assessments
Non-Motor Measures
Digital Endpoints
The ICPD maintains close relationships with other major gatherings:
The Congress also addresses related conditions:
The ICPD plays a crucial role in:
Advancing Research
Improving Care
Patient Advocacy
International Parkinson and Movement Disorders Society. ↩︎ ↩︎
Bloem BR, Okun MS, Nieuwboer A. The Parkinson's disease pandemic: A call to action. Nat Rev Neurol. 2024. 2024. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. 2015. ↩︎
Foltin J, et al. alpha-Synuclein immunotherapy for Parkinson's disease: Current status and future prospects. Pharmacol Ther. 2023. 2023. ↩︎
Mikhailova N, et al. LRRK2 kinase inhibitors in Parkinson's disease: Current status and future directions. Brain. 2024. 2024. ↩︎
Axelsen T, et al. GBA gene mutations and Parkinson's disease: Clinical implications and therapeutic strategies. Mov Disord. 2024. 2024. ↩︎
Caceres A, et al. Neuroinflammation in Parkinson's disease: From pathophysiology to therapeutic targets. Nat Rev Neurosci. 2024. 2024. ↩︎
Weinberger M, et al. Deep brain stimulation for Parkinson's disease: Mechanisms and optimization. Brain. 2024. 2024. ↩︎
Michael J, et al. Deep brain stimulation for Parkinson's disease: Advances and controversies. Brain. 2023. 2023. ↩︎
Bhatia KP, et al. Non-motor symptoms in Parkinson's disease. Nat Rev Dis Primers. 2023. 2023. ↩︎
Aarsland D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2021. 2021. ↩︎